Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2-Reference-Cited by-同舟云学术

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

Published:2012-01-12 Issue:4 Volume:106 Page:673-677
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Brain E,Isambert N,Dalenc F,Diéras V,Bonneterre J,Rezai K,Jimenez M,Mefti-Lacheraf F,Cottura E,Tresca P,Vanlemmens L,Mahier-Aït Oukhatar C,Lokiec F,Fumoleau P

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2011591.pdf

Reference26 articles.

1. Bai F, Freeman III BB, Fraga CH, Fouladi M, Stewart CF (2006) Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 831: 169–175

2. Blackwell K, Kaplan EH, Franco SX, Marcom PK, Maleski J, Sorensen M, Berger MS (2004) A phase II open-label, multcenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens. Ann Oncol 15 (suppl 3): 27 (Abstract 103O)

3. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722–2730

4. Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19: 1068–1074

5. Chan A (2007) A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 18: 1152–1158

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy;Hematological Oncology;2016-12-07

2. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial;BMC Cancer;2016-02-18

3. Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations;Translational Oncology;2016-02

4. A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study);Clinical Breast Cancer;2016-02

5. Metabolism‐related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations;British Journal of Clinical Pharmacology;2015-01-20